White Guide and Orange Guide Formatting Project - Pfizer

Orange Guide – Chapter 6: Clinical Research and Investigator-Initiated Research
Chapter 6: CLINICAL RESEARCH AND
INVESTIGATOR-INITIATED RESEARCH
CONTENTS
Clinical Research and Investigator-Initiated Research
Supporting Legitimate Medical Research ....................................................................................................................2
Key Points to Ensure Compliance ......................................................................................................................... 3
Types of Funding or Support ......................................................................................................................................... 3
Pfizer-Sponsored Trials ........................................................................................................................................ 4
Investigator-Initiated Research Grants ................................................................................................................ 5
Requests for Study Medication or Pure Substance ............................................................................................ 6
“Compassionate Use” Requests ................................................................................................................................... 6
Responding to Requests from HCPs Regarding Medical Research ............................................................................ 7
Responding to Requests to be a Clinical Investigator .......................................................................................... 7
No Assistance with IIR Protocols ......................................................................................................................... 8
No Assistance with Patient Recruitment ............................................................................................................ 8
FOR MORE INFORMATION ......................................................................................................................................... 9
114
Rev. 09/12
Page 1 of 9